Aeolus to Develop Candidate for Parkinson's
Posted on: Wednesday, 21 June 2006, 15:00 CDT
Aeolus Pharmaceuticals has selected a compound that has shown potential in models of Parkinson's disease as its first development candidate from its "pipeline initiative".
The compound, AEOL 11207, has shown potential in preclinical testing as a once-every-other-day oral therapeutic treatment option for a number of CNS disorders, most likely Parkinson's disease. However, the company said that it has not yet fully determined what the most robust therapeutic use of the compound might be.
A biological hallmark of Parkinson's disease is a reduction in brain dopamine levels. Preventing or slowing the destruction of brain cells that lead to the depletion of dopamine levels in the brain is an important therapeutic approach for the treatment of this disease.
Data developed with AEOL 11207 in a widely used animal model of Parkinson's disease showed that when administered orally, AEOL 11207 crosses the blood brain barrier and protected dopamine neurons in a dose-dependent manner.
Data also indicates that when administered orally, the compound is greater than 80% bioavailable, meaning that it is readily absorbed and reaches both the circulatory system and the brain in sufficient amounts to demonstrate biological activity.
"For this and other reasons, the company believes that the therapeutic rationale for developing AEOL 11207 as a neuroprotectant, may substantially change the course of therapeutic treatment options for Parkinson's disease if AEOL 11207 were to achieve regulatory approval for commercialization," said the company in a statement.
Source: Datamonitor
Related Articles
- ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tolls for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
- Stakeholder Insight: Parkinson's Disease - Evidence of Neuroprotection Essential to Progress Treatment Dynamics
- U.S. Breast Disease Diagnostic and Therapeutic Devices Market Poised to Grow to Over $2.7 Billion By 2012
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
- New Brain Cancer Treatment is Evaluated
- Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus
- Power3 Identifies Early-Detection Biomarkers for Parkinson's Disease; Can Differentiate Between Parkinson's and Parkinson's-Like Diseases at Early Stages
- GeneEd Releases Comprehensive Database of Disease State and Therapeutic Area (TA) E-Learning
- Setting the Benchmark in Brain Tumor Treatment at The University of Texas M. D. Anderson Cancer Center
 |
 |
User Comments (0)
RSS Feeds